== (A) Bronchoscopy shows a polypoid mass in the entrance to the left main bronchus prior to chemotherapy

== (A) Bronchoscopy shows a polypoid mass in the entrance to the left main bronchus prior to chemotherapy. a case of metastatic ascending colon cancer harboring aKRASp.G13D mutation in which the patient responded well to first-line therapy with FOLFOX4 + Cmab. Keywords:colon cancer,KRASp.G13D mutation, cetuximab == Intro == Cetuximab (Cmab), a monoclonal antibody that specifically binds to and inhibits the activity of human being epidermal growth element receptor (EGFR), is used like a molecularly targeted anticancer agent. The antitumor activities of Cmab are believed to be limited to wild-typeKRAStumors, and indications for its use are consequently limited to Cinchonidine such instances. Recently, however, a number of studies possess reported Cmab to also be effective againstKRASp.G13D mutant-type tumors (13). We recently experienced a case of metastatic ascending colon cancer harboring aKRASp.G13D mutation that responded Cinchonidine well to FOLFOX4 [folinic acid (FOL), fluorouracil (F) plus oxaliplatin (OX)] + Cmab therapy, which we present in this study. == Case statement == The patient was a 65-year-old female. Chest X-rays performed at another hospital as part of an annual health checkup exposed granular shadows in both lung fields. The patient was consequently referred to our Division of Respiratory Medicine in November 2010, and a detailed, whole-body exam was performed. A chest X-ray confirmed several granular shadows in both lung fields (Fig. 1A). == Number 1. == Chest X-ray showing (A) several granular shadows in both lung fields prior to chemotherapy. (B) Disappearance or size reduction in some granular shadows was observed following chemotherapy. Computed tomography of the thorax exposed several nodular lesions in both lung fields and a nodular lesion in the entrance to the left main bronchus (Fig. 2A). == Number 2. == Thorax CT exposed (A) several nodular lesions in both lung fields; a nodular lesion was observed in the entrance to the left main bronchus prior to chemotherapy. (B) Disappearance or size reduction in some granular lesions was observed following chemotherapy. The nodular lesion observed in the entrance to the left main bronchus disappeared after chemotherapy. Bronchoscopy exposed a polypoid mass in the entrance to the left main bronchus. The biopsy specimen was pathologically ranked as adenocarcinoma, suggesting metastasis of colorectal tubular adenocarcinoma (Fig. 3A). == Number 3. == (A) Bronchoscopy shows a polypoid mass in the entrance to the left main bronchus prior to chemotherapy. (B) Only mild redness is visible; no tumorous lesion was observed following chemotherapy. Colonoscopy exposed a tumorous lesion in the lumen of the ascending colon (Fig. 4A). The biopsy specimen was pathologically ranked like a moderately differentiated tubular adenocarcinoma. == Number 4. == (A) Colonoscopy shows a tumorous lesion in lumen of the ascending colon before chemotherapy. (B) The lesion experienced disappeared. Converging mucosal folds accompanied by redness following chemotherapy are demonstrated. Based on these findings, ascending colon cancer with multiple lung metastases was diagnosed and the Cinchonidine patient was referred to the Division of Surgery, where medical resection of the primary malignancy was initially regarded as. However, considering the absence of symptoms at Rabbit Polyclonal to C-RAF (phospho-Ser301) the time of referral and the post-operative risk of respiratory complications, anticancer drug therapy was selected as first-line therapy, and FOLFOX4 was started in mid-December. Four days after the 1st session of FOLFOX4 therapy, the patient was urgently hospitalized for severe nausea. Treatment with aprepitant alleviated these symptoms, permitting the patient to be discharged from the hospital within the fourth hospital day. Later on, aKRAStest exposed aKRASp.G13D mutation. Consequently, with educated consent, FOLFOX4 therapy was combined with weekly Cmab early in January 2011. The response to chemotherapy was evaluated following 2 classes of FOLFOX therapy and 2 subsequent classes of FOLFOX4 + Cmab therapy. A chest X-ray exposed the presence of several granular shadows in both lung fields. There was, however, disappearance or reduction in size of particular granular shadows compared with the previous X-ray (Fig. 1B). A thoracic CT check out exposed the continued presence of numerous nodular lesions in both lung fields. There was, however, disappearance or reduction in size of particular granular shadows compared with the previous CT check out. The nodular lesion observed in the entrance to the left main bronchus prior to treatment had disappeared (Fig. 2B). Bronchoscopy exposed only mild redness and no tumorous lesion in the remaining main bronchus (Fig. 3B). Colonoscopy exposed the tumorous lesion in the lumen of the ascending colon.